These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38277735)

  • 21. Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder.
    Lee DC; Schlienz NJ; Herrmann ES; Martin EL; Leoutsakos J; Budney AJ; Smith MT; Tompkins DA; Hampson AJ; Vandrey R
    J Subst Use Addict Treat; 2024 Jan; 156():209180. PubMed ID: 37802317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of pregabalin maintenance on cannabis effects and related behaviors in daily cannabis users.
    Lile JA; Alcorn JL; Hays LR; Kelly TH; Stoops WW; Wesley MJ; Westgate PM
    Exp Clin Psychopharmacol; 2022 Oct; 30(5):560-574. PubMed ID: 33983765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abstinence based incentives plus parent training for adolescent alcohol and other substance misuse.
    Stanger C; Scherer EA; Babbin SF; Ryan SR; Budney AJ
    Psychol Addict Behav; 2017 Jun; 31(4):385-392. PubMed ID: 28414474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contingency management for alcohol use disorder reduces cannabis use among American Indian and Alaska Native adults.
    Hirchak KA; Lyons AJ; Herron JL; Kordas G; Shaw JL; Jansen K; Avey JP; McPherson SM; Donovan D; Roll J; Buchwald D; Ries R; McDonell MG;
    J Subst Abuse Treat; 2022 Jun; 137():108693. PubMed ID: 34952747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder.
    Sahlem GL; Kim B; Baker NL; Wong BL; Caruso MA; Campbell LA; Kaloani I; Sherman BJ; Ford TJ; Musleh AH; Kim JP; Williams NR; Manett AJ; Kratter IH; Short EB; Killeen TK; George MS; McRae-Clark AL
    Drug Alcohol Depend; 2024 Jan; 254():111035. PubMed ID: 38043228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
    Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
    Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A method to achieve extended cannabis abstinence in cannabis dependent patients with schizophrenia and non-psychiatric controls.
    Rabin RA; Kozak K; Zakzanis KK; Remington G; Stefan C; Budney AJ; George TP
    Schizophr Res; 2018 Apr; 194():47-54. PubMed ID: 28506704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Working memory training and high magnitude incentives for youth cannabis use: A SMART pilot trial.
    Stanger C; Scherer EA; Vo HT; Babbin SF; Knapp AA; McKay JR; Budney AJ
    Psychol Addict Behav; 2020 Feb; 34(1):31-39. PubMed ID: 31246068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial.
    Lintzeris N; Mills L; Dunlop A; Copeland J; Mcgregor I; Bruno R; Kirby A; Montebello M; Hall M; Jefferies M; Kevin R; Bhardwaj A;
    Drug Alcohol Depend; 2020 Oct; 215():108220. PubMed ID: 32768992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use.
    Lee DC; Budney AJ; Brunette MF; Hughes JR; Etter JF; Stanger C
    Drug Alcohol Depend; 2015 Oct; 155():134-40. PubMed ID: 26307942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled trial of motivational enhancement therapy with nontreatment-seeking adolescent cannabis users: a further test of the teen marijuana check-up.
    Walker DD; Stephens R; Roffman R; Demarce J; Lozano B; Towe S; Berg B
    Psychol Addict Behav; 2011 Sep; 25(3):474-84. PubMed ID: 21688877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
    Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
    Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.
    Gray KM; Sonne SC; McClure EA; Ghitza UE; Matthews AG; McRae-Clark AL; Carroll KM; Potter JS; Wiest K; Mooney LJ; Hasson A; Walsh SL; Lofwall MR; Babalonis S; Lindblad RW; Sparenborg S; Wahle A; King JS; Baker NL; Tomko RL; Haynes LF; Vandrey RG; Levin FR
    Drug Alcohol Depend; 2017 Aug; 177():249-257. PubMed ID: 28623823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combining cognitive behavioral therapy and contingency management to enhance their effects in treating cannabis dependence: less can be more, more or less.
    Carroll KM; Nich C; Lapaglia DM; Peters EN; Easton CJ; Petry NM
    Addiction; 2012 Sep; 107(9):1650-9. PubMed ID: 22404223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial.
    Trigo JM; Soliman A; Quilty LC; Fischer B; Rehm J; Selby P; Barnes AJ; Huestis MA; George TP; Streiner DL; Staios G; Le Foll B
    PLoS One; 2018; 13(1):e0190768. PubMed ID: 29385147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial.
    Freeman TP; Hindocha C; Baio G; Shaban NDC; Thomas EM; Astbury D; Freeman AM; Lees R; Craft S; Morrison PD; Bloomfield MAP; O'Ryan D; Kinghorn J; Morgan CJA; Mofeez A; Curran HV
    Lancet Psychiatry; 2020 Oct; 7(10):865-874. PubMed ID: 32735782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of Cannabis Use Disorder and Reasons for Use Among Adults in a US State Where Recreational Cannabis Use Is Legal.
    Lapham GT; Matson TE; Bobb JF; Luce C; Oliver MM; Hamilton LK; Bradley KA
    JAMA Netw Open; 2023 Aug; 6(8):e2328934. PubMed ID: 37642968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fitness to drive and cannabis: validation of two blood THCCOOH thresholds to distinguish occasional users from heavy smokers.
    Fabritius M; Augsburger M; Chtioui H; Favrat B; Giroud C
    Forensic Sci Int; 2014 Sep; 242():1-8. PubMed ID: 24999608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-abstinent treatment outcomes for cannabis use disorder.
    Levin FR; Mariani JJ; Choi CJ; Basaraba C; Brooks DJ; Brezing CA; Pavlicova M
    Drug Alcohol Depend; 2021 Aug; 225():108765. PubMed ID: 34087745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinence.
    Martin EL; Baker NL; Sempio C; Christians U; Klawitter J; McRae-Clark AL
    Addict Biol; 2023 Oct; 28(10):e13337. PubMed ID: 37753564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.